A share price of Climb Bio Inc [CLYM] is currently trading at $1.39, up 12.10%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CLYM shares have gain 17.80% over the last week, with a monthly amount glided 14.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Climb Bio Inc [NASDAQ: CLYM] stock has seen the most recent analyst activity on June 06, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $10. Previously, BTIG Research started tracking the stock with Buy rating on May 22, 2025, and set its price target to $7. On December 02, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $10 on the stock.
Climb Bio Inc experienced fluctuations in its stock price throughout the past year between $1.05 and $9.49. Climb Bio Inc [NASDAQ: CLYM] shares were valued at $1.39 at the most recent close of the market.
Analyzing the CLYM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.39 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2833 points at the first support level, and at 1.1767 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4833, and for the 2nd resistance point, it is at 1.5767.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Climb Bio Inc [NASDAQ:CLYM] is 14.25. As well, the Quick Ratio is 14.25, while the Cash Ratio is 17.69.
Transactions by insiders
Recent insider trading involved Pimblett Emily, SVP, Finance & CAO, that happened on Mar 20 ’25 when 1199.0 shares were sold. CHIEF ACCOUNTING OFFICER, Pimblett Emily completed a deal on Dec 19 ’24 to sell 1235.0 shares. Meanwhile, CHIEF ACCOUNTING OFFICER Pimblett Emily sold 1191.0 shares on Sep 20 ’24.
